DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,113 | +2.2% | 82,367 | +11.5% | 0.13% | +10.3% |
| Q2 2023 | $17,727 | +2.6% | 73,862 | +7.7% | 0.12% | -2.5% |
| Q1 2023 | $17,279 | -5.4% | 68,559 | -0.4% | 0.12% | -14.3% |
| Q4 2022 | $18,272 | -99.9% | 68,840 | +2.2% | 0.14% | -3.4% |
| Q3 2022 | $17,401,000 | +7.5% | 67,375 | +5.5% | 0.14% | +16.9% |
| Q2 2022 | $16,186,000 | -5.5% | 63,845 | +9.3% | 0.12% | +15.9% |
| Q1 2022 | $17,133,000 | +13.5% | 58,409 | +27.3% | 0.11% | +20.2% |
| Q4 2021 | $15,100,000 | +5.2% | 45,896 | -2.7% | 0.09% | -5.3% |
| Q3 2021 | $14,358,000 | +7.3% | 47,161 | -5.5% | 0.09% | +4.4% |
| Q2 2021 | $13,387,000 | +21.1% | 49,887 | +1.5% | 0.09% | +9.8% |
| Q1 2021 | $11,057,000 | -11.4% | 49,126 | -12.6% | 0.08% | -14.6% |
| Q4 2020 | $12,482,000 | +74.4% | 56,191 | +69.1% | 0.10% | +47.7% |
| Q3 2020 | $7,157,000 | +13.1% | 33,236 | -56.6% | 0.06% | -51.1% |
| Q2 2020 | $6,327,000 | -40.4% | 76,661 | 0.0% | 0.13% | +20.9% |
| Q1 2020 | $10,611,000 | +15.3% | 76,661 | +27.8% | 0.11% | +44.7% |
| Q4 2019 | $9,203,000 | -4.8% | 59,968 | -10.4% | 0.08% | -7.3% |
| Q3 2019 | $9,671,000 | +0.0% | 66,960 | -1.0% | 0.08% | -3.5% |
| Q2 2019 | $9,667,000 | +5.9% | 67,643 | -2.1% | 0.08% | +6.2% |
| Q1 2019 | $9,125,000 | +46.0% | 69,114 | +14.0% | 0.08% | +33.3% |
| Q4 2018 | $6,250,000 | -47.2% | 60,604 | -44.4% | 0.06% | -39.4% |
| Q3 2018 | $11,838,000 | -10.5% | 108,947 | -18.7% | 0.10% | -4.8% |
| Q2 2018 | $13,231,000 | -1.3% | 134,088 | -2.1% | 0.10% | -2.8% |
| Q1 2018 | $13,405,000 | +34.1% | 136,920 | +27.1% | 0.11% | +50.7% |
| Q4 2017 | $9,998,000 | +529.2% | 107,712 | +481.4% | 0.07% | +545.5% |
| Q3 2017 | $1,589,000 | +6.7% | 18,525 | +5.0% | 0.01% | +10.0% |
| Q2 2017 | $1,489,000 | +0.3% | 17,650 | +1.7% | 0.01% | +11.1% |
| Q1 2017 | $1,484,000 | -3.4% | 17,350 | -12.2% | 0.01% | -10.0% |
| Q4 2016 | $1,537,000 | -41.2% | 19,750 | -40.8% | 0.01% | -37.5% |
| Q3 2016 | $2,616,000 | -48.5% | 33,381 | -49.7% | 0.02% | -46.7% |
| Q2 2016 | $5,084,000 | +272.2% | 66,421 | +361.3% | 0.03% | +233.3% |
| Q1 2016 | $1,366,000 | -27.2% | 14,400 | -28.7% | 0.01% | -25.0% |
| Q4 2015 | $1,876,000 | +9.5% | 20,200 | +0.5% | 0.01% | 0.0% |
| Q3 2015 | $1,713,000 | +38.0% | 20,100 | +38.6% | 0.01% | +33.3% |
| Q2 2015 | $1,241,000 | +0.8% | 14,500 | 0.0% | 0.01% | +12.5% |
| Q1 2015 | $1,231,000 | -28.1% | 14,500 | -27.3% | 0.01% | -33.3% |
| Q4 2014 | $1,711,000 | +5.2% | 19,950 | -6.8% | 0.01% | 0.0% |
| Q3 2014 | $1,626,000 | -9.0% | 21,400 | -5.7% | 0.01% | -7.7% |
| Q2 2014 | $1,787,000 | -6.2% | 22,700 | -10.6% | 0.01% | -13.3% |
| Q1 2014 | $1,905,000 | -4.7% | 25,400 | -1.9% | 0.02% | -11.8% |
| Q4 2013 | $1,999,000 | +5.3% | 25,900 | -5.5% | 0.02% | +13.3% |
| Q3 2013 | $1,899,000 | +7.9% | 27,400 | -1.4% | 0.02% | +15.4% |
| Q2 2013 | $1,760,000 | – | 27,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |